Mai Nguyen-Huynh
Overview
Explore the profile of Mai Nguyen-Huynh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang Y, Kwan M, Heckbert S, Smith N, Othus M, Laurent C, et al.
J Natl Cancer Inst
. 2025 Mar;
PMID: 40071691
Background: There are increasing concerns of cardiovascular safety related to endocrine therapy use in women with breast cancer (BC). We examined risk of cardiovascular disease (CVD) events and mortality associated...
2.
Ergas I, Cheng R, Roh J, Kresovich J, Iribarren C, Nguyen-Huynh M, et al.
Breast Cancer Res Treat
. 2025 Jan;
PMID: 39890673
Purpose: Breast cancer (BC) survivors experience higher rates of cardiometabolic conditions, partly due to treatment. While healthy eating decreases the risk of these conditions in the general population, its association...
3.
Huang Y, Kwan M, Heckbert S, Smith N, Othus M, Laurent C, et al.
JNCI Cancer Spectr
. 2025 Jan;
9(1).
PMID: 39873699
Background: There are limited data on duration of aromatase inhibitor (AI) and cardiovascular disease (CVD) risk in breast cancer (BC) survivors. We examined the risk of CVD and mortality associated...
4.
Bushnell C, Kernan W, Sharrief A, Chaturvedi S, Cole J, Cornwell 3rd W, et al.
Stroke
. 2024 Oct;
55(12):e344-e424.
PMID: 39429201
Aim: The "2024 Guideline for the Primary Prevention of Stroke" replaces the 2014 "Guidelines for the Primary Prevention of Stroke." This updated guideline is intended to be a resource for...
5.
Kwan M, Pimentel N, Izano M, Iribarren C, Rana J, Nguyen-Huynh M, et al.
PLoS One
. 2024 Sep;
19(9):e0310531.
PMID: 39298390
Purpose: Women with breast cancer (BC) are at high risk of developing cardiovascular disease (CVD). We examined adherence to CVD medications and their association with major CVD events over 14...
6.
Ergas I, Cheng R, Roh J, Kushi L, Kresovich J, Iribarren C, et al.
JNCI Cancer Spectr
. 2024 Apr;
8(2).
PMID: 38627946
Background: Women with breast cancer are at higher risk of cardiovascular disease (CVD) compared with women without breast cancer. Whether higher diet quality at breast cancer diagnosis lowers this risk...
7.
Rillamas-Sun E, Kwan M, Iribarren C, Cheng R, Neugebauer R, Rana J, et al.
Breast Cancer Res Treat
. 2023 Jun;
201(1):117-126.
PMID: 37326764
Purpose: Studies comparing the effect of aromatase inhibitor (AI) and tamoxifen use on cardiovascular disease (CVD) risk factors in hormone receptor-positive breast cancer (BC) survivors report conflicting results. We examined...
8.
Rillamas-Sun E, Kwan M, Carlos C, Cheng R, Neugebauer R, Rana J, et al.
Res Sq
. 2023 Mar;
PMID: 36993531
Purpose: Studies comparing the effect of aromatase inhibitor (AI) and tamoxifen use on cardiovascular disease (CVD) risk factors in hormone-receptor positive breast cancer (BC) survivors report conflicting results. We examined...
9.
Greenlee H, Rillamas-Sun E, Cheng R, Iribarren C, Rana J, Nguyen-Huynh M, et al.
J Clin Oncol
. 2022 Jul;
40(35):4159-4160.
PMID: 35878101
No abstract available.
10.
Greenlee H, Iribarren C, Rana J, Cheng R, Nguyen-Huynh M, Rillamas-Sun E, et al.
J Clin Oncol
. 2022 Apr;
40(15):1647-1658.
PMID: 35385342
Purpose: To examine cardiovascular disease (CVD) and mortality risk in women with breast cancer (BC) by cancer therapy received relative to women without BC. Methods: The study population comprised Kaiser...